Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-N001 in Advanced Gastrointestinal Tumors
NCT07826195Phase 2Not yet recruiting
- Sponsor
- Zhejiang Anglikang Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label trial of QHL-1618 in gastrointestinal tumor, Esophageal Squamous Cell Carcinoma (ESCC) and colorectal carcinoma (CRC) (6 cohorts), sponsored by Zhejiang Anglikang Pharmaceutical. Primary endpoint: Objective Response Rate at 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
QHL-1618
03
Conditions
gastrointestinal tumorEsophageal Squamous Cell Carcinoma (ESCC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT07826195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07826195.